drugset / Trial / NCT04385836

Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

NCT04385836 ↗

Phase 0 Unknown 150 enrolled Ministry of Health, Saudi Arabia
RandomizedParallel-groupSingle-blindTreatment

Summary

It is clear now that SARS-CoV-2 could use angiotensin-converting enzyme 2 (ACE2), the same receptor as SARS-CoV Transmembrane protease serine type 2 (TMPRSS2), a protease belonging to the type II transmembrane serine protease family, cleaves the coronavirus spike protein Serine proteases are inhibited by a diverse group of inhibitors, The best-studied serpins are antithrombin and alpha 1-antitrypsin

Timeline

Start
2020-06-01
Primary completion
2020-09-01
Completion
2020-09-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator alpha one antitrypsin Unknown 8 ml Inhaled